glp 1 for chronic kidney disease GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Study uncovers how chronic kidney
Description
Comparative effectiveness of basal-bolus versus premix analog insulin on glycemic variability and patient-centered outcomes during insulin intensification in type 1 and type 2 diabetes: a randomized, controlled, crossover trial
It supports arguments that the drug manufacturer should have developed a safer drug or disclosed the risk in warnings, labeling, or during marketing
semaglutide: 0) such as nausea and vomiting
Clean, easy-to-read layout
F1000Research , 3 , 157
Known for innovation and a robust pipeline, contributing through advanced treatments and expanding the market reach
